AbbVie Inc. (NYSE:ABBV) Given Consensus Recommendation of “Moderate Buy” by Analysts

Shares of AbbVie Inc. (NYSE:ABBV) have received an average rating of “Moderate Buy” from the twenty-four analysts that are covering the stock, MarketBeat.com reports. Eight analysts have rated the stock with a hold rating, thirteen have given a buy rating and three have given a strong buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $245.8421.

A number of research analysts recently commented on the company. Scotiabank assumed coverage on AbbVie in a research note on Thursday, November 13th. They issued a “sector outperform” rating and a $280.00 price target for the company. Berenberg Bank upgraded shares of AbbVie from a “hold” rating to a “buy” rating and boosted their target price for the company from $170.00 to $270.00 in a research report on Wednesday, September 17th. BMO Capital Markets increased their price target on shares of AbbVie from $215.00 to $240.00 and gave the stock an “outperform” rating in a research report on Friday, September 12th. Erste Group Bank cut shares of AbbVie from a “buy” rating to a “hold” rating in a research note on Tuesday, October 14th. Finally, Cantor Fitzgerald set a $250.00 target price on AbbVie and gave the company an “overweight” rating in a report on Thursday, October 9th.

AbbVie Trading Up 0.1%

AbbVie stock opened at $230.07 on Friday. The company has a debt-to-equity ratio of 44.14, a quick ratio of 0.60 and a current ratio of 0.72. The stock has a market capitalization of $406.63 billion, a P/E ratio of 174.30, a PEG ratio of 1.31 and a beta of 0.36. AbbVie has a 52 week low of $164.39 and a 52 week high of $244.81. The stock has a 50-day simple moving average of $226.73 and a 200 day simple moving average of $212.57.

AbbVie (NYSE:ABBV) last announced its quarterly earnings results on Friday, October 31st. The company reported $1.86 EPS for the quarter, beating analysts’ consensus estimates of $1.77 by $0.09. AbbVie had a net margin of 4.00% and a return on equity of 3,216.47%. The business had revenue of $15.78 billion for the quarter, compared to analyst estimates of $15.58 billion. During the same quarter in the prior year, the business earned $3.00 EPS. AbbVie’s quarterly revenue was up 9.1% on a year-over-year basis. AbbVie has set its Q4 2025 guidance at 3.320-3.360 EPS. Analysts expect that AbbVie will post 12.31 earnings per share for the current year.

AbbVie Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Tuesday, February 17th. Stockholders of record on Friday, January 16th will be paid a $1.73 dividend. This represents a $6.92 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date is Friday, January 16th. This is a positive change from AbbVie’s previous quarterly dividend of $1.64. AbbVie’s dividend payout ratio is currently 496.97%.

Institutional Investors Weigh In On AbbVie

Several hedge funds have recently added to or reduced their stakes in ABBV. Marshall & Sullivan Inc. WA acquired a new stake in AbbVie in the second quarter valued at $25,000. Evolution Wealth Management Inc. bought a new stake in shares of AbbVie in the 2nd quarter valued at about $26,000. Chelsea Counsel Co. acquired a new stake in shares of AbbVie in the third quarter valued at about $26,000. Spurstone Advisory Services LLC bought a new position in shares of AbbVie during the second quarter worth about $28,000. Finally, Texas Capital Bancshares Inc TX acquired a new position in shares of AbbVie in the third quarter worth approximately $31,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

About AbbVie

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.